An observational cohort study to examine aquaporin-4 antibody dynamics in neuromyelitis optica spectrum disorder

A cohort study to investigate serum aquarporin-4 antibody (AQP4-IgG) dynamics and its association with relapse in persons with AQP4-IgG seropositive neuromyelitis optica spectrum disorder, treated with immunosuppressants.
After treatment, 128 patients became AQP4-IgG seronegative. The mean annualized relapse rate significantly decreased after patients became seronegative (0.20 vs. 0.77, P<0.001).
Authors concluded that patients with a younger age at onset, poly-system involvement in the first attack, and unchanged or increased AQP4-IgG titer, had an increased relapse risk.